At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Bimekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis.
In Brief
A Phase 2 clinical trial evaluating Bimekizumab for Chronic Plaque Psoriasis. Completed, enrolled 43 participants across 10 sites in 4 countries.
Detailed Summary
This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis
CountriesAustralia, Canada, Moldova, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedJul 2017
Primary CompletionMar 2019
TodayJul 2026
First PostedJul 26, 2017
Enrollment StartJul 3, 2017
Primary CompletionMar 6, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.9 years ago
Interventions
Bimekizumabdrug
Bimekizumab will be administered subcutaneously in 2 different doses.